ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 84 filers reported holding ORIC PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,049,699 | -9.0% | 3,479,289 | +16.8% | 0.04% | -5.0% |
| Q2 2023 | $23,119,283 | +69.1% | 2,979,289 | +24.2% | 0.04% | +33.3% |
| Q1 2023 | $13,675,737 | -3.2% | 2,399,252 | 0.0% | 0.03% | -45.5% |
| Q4 2022 | $14,131,594 | +109.6% | 2,399,252 | +13.9% | 0.06% | +150.0% |
| Q3 2022 | $6,742,000 | -28.6% | 2,106,968 | 0.0% | 0.02% | -12.0% |
| Q2 2022 | $9,439,000 | -7.3% | 2,106,968 | +10.5% | 0.02% | +25.0% |
| Q1 2022 | $10,183,000 | -51.5% | 1,906,968 | +33.6% | 0.02% | -48.7% |
| Q4 2021 | $20,977,000 | +0.6% | 1,426,968 | +43.1% | 0.04% | +11.4% |
| Q3 2021 | $20,847,000 | +18.2% | 996,989 | 0.0% | 0.04% | +34.6% |
| Q2 2021 | $17,637,000 | -27.9% | 996,989 | -0.1% | 0.03% | -27.8% |
| Q1 2021 | $24,452,000 | -19.6% | 998,061 | +11.1% | 0.04% | -26.5% |
| Q4 2020 | $30,399,000 | +301.1% | 898,061 | +196.3% | 0.05% | +250.0% |
| Q3 2020 | $7,579,000 | – | 303,061 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 4,768,181 | $161,403,000 | 14.64% |
| Invus Financial Advisors, LLC | 1,007,575 | $34,106,000 | 14.26% |
| Euclidean Capital LLC | 1,400,435 | $47,405,000 | 10.04% |
| Memorial Sloan Kettering Cancer Center | 602,272 | $20,387,000 | 8.63% |
| EcoR1 Capital, LLC | 3,092,218 | $104,672,000 | 5.63% |
| Ally Bridge Group (NY) LLC | 413,061 | $13,982,000 | 2.40% |
| Asymmetry Capital Management, L.P. | 67,210 | $2,275,000 | 1.04% |
| Orbimed Advisors | 2,921,967 | $98,909,000 | 0.86% |
| Casdin Capital, LLC | 601,515 | $20,361,000 | 0.60% |
| EMERALD ADVISERS, LLC | 522,302 | $17,680,000 | 0.59% |